The CARDIO-TTRansform Scintigraphy Sub-study

Running, not enrolling

Conditions studied: Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)

In brief

The purpose of this study is to examine the changes in amyloid myocardial burden in a subset of the population participating in the ION682884-CS2 (NCT04136171) study, up to 150 participants, after treatment with eplontersen or placebo based on scintigraphy scans performed at Week 140 using the Perugini grade score method.

Key facts

Study ID

NCT06073587

Run by

Ionis Pharmaceuticals, Inc.

People needed

150

Starts

2023-04-04

Expected to finish

2026-03-01

Last updated by the study team

2025-11-28

Who can join

Age: 18 and older, up to 90. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants must have been properly randomized into the ION-682884-CS2 study (NCT04136171) and should have had a baseline scintigraphy scan (99mTc-DPD, 99mTc- PYP, and 99mTc-HMDP) within 12 months prior to screening for ION-682884-CS2 with planar and SPECT or SPECT/CT images that can be read by the central reader.

You may not qualify if…

• Must not meet any of the exclusion criteria of the study protocol ION-682884-CS2 (NCT04136171).
• Must not have weight or body girth that exceeds the limits of the equipment specifications.
• Should not have any previously reported hypersensitivity reaction to Technetium-99m.

Where it is running

• Columbia University Irving Medical Center — New York, New York, United States
• Duke University Medical Center — Durham, North Carolina, United States
• Cleveland Clinic Main Campus — Cleveland, Ohio, United States
• Oregon Health and Science University — Portland, Oregon, United States
• Hospital Universitario Puerta de Hierro — Majadahonda, Spain

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.